Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Vaccines & Immunizations








CDC COVID-19 Vaccination Program Provider Requirements and Support						Print
																Related Pages
										Illustrations of healthcare professionals talking to patients about COVID-19 vaccination.
**10/6/2023 Update**The US government is no longer purchasing COVID-19 vaccines; therefore, the CDC COVID-19 Vaccination Program has ended. Updated 2023–2024 COVID-19 vaccines are now available for private purchase in the commercial marketplace.On Monday, Sept. 11, 2023, the FDA took action authorizing and approving the updated 2023–2024 monovalent XBB.1.5 variant mRNA COVID-19 vaccines by Moderna and Pfizer-BioNTech. On September 12, 2023, CDC recommended use of these updated 2023–2024 COVID-19 vaccines in all individuals ages 6 months and older.
And, on October 3, 2023, FDA authorized the updated 2023–2024 monovalent XBB.1.5 variant Novavax COVID-19 Vaccine, Adjuvanted, which is recommended by CDC for use in individuals 12 years and older.CDC has also withdrawn previous recommendations for use of the earlier versions of COVID-19 vaccines.
		**On This Page**
			Closing Out the CDC COVID-19 Vaccination Program
		

CDC COVID-19 Vaccination Program **Has Ended**
With these FDA and CDC actions, the CDC COVID-19 Vaccination Program ended as of September 12, 2023*,*as it applied to the administration of the bivalent Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines previously provided by the US Government (USG). Now, with FDA’s authorization on October 3, 2023, of the 2023–2024 Novavax COVID-19 Vaccine, Adjuvanted, the CDC COVID-19 Vaccination Program has fully ended as of October 3, 2023. All authorized/approved doses of COVID-19 vaccine in the United States are now the 2023–2024 formulas.
See below for required close-out activities for enrolled providers, including those enrolled through the jurisdictions and through the Federal Retail Pharmacy Program (FRPP), and other commercial partners, as well as federal and tribal entities participating in the CDC COVID-19 Vaccination Program.
Bivalent (Original and Omicron BA.4/BA.5 variant) Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines and ancestral (Original) Novavax COVID-19 vaccines should no longer be administered; 2023-2024 versions should be administered instead.
With the end of USG-purchase of COVID-19 vaccines for administration through the CDC COVID-19 Vaccination Program,**providers are encouraged to continue administering COVID-19 vaccines through their offices/pharmacies/other practices by:**
Commercially procuring doses of the updated 2023–2024 COVID-19 vaccine(s),
Participating in the vaccines.gov vaccine locator service to help inform patients regarding availability of COVID-19 vaccine at their medical/pharmacy/other practice, and
Otherwise informing their patients of CDC recommendations for receipt of the updated 2023–2024 monovalent XBB-containing COVID-19 vaccines.**Details on the CDC COVID-19 Vaccination Program discontinuation and required closeout activities are noted below. (Updated October 6, 2023)**
This page serves as repository for any updates to the **CDC COVID-19 Vaccination Program Provider Agreement**, including recommendations, requirements, and other useful information for vaccination providers enrolled in the program.CDC COVID-19 Vaccination Program Provider Agreement
UPDATES – CDC COVID-19 Vaccination Program Provider Agreement RequirementsClosing Out the CDC COVID-19 Vaccination Program (Updated 10/6/2023)**Step One: Reporting and Disposal of Remaining USG-Provided Vaccine Inventory**
From the Program’s beginning, the COVID-19 Vaccination Program Provider Agreement has required all enrolled providers to report the number of unused, spoiled, expired, or wasted vaccine doses. Now, with the Program ended, providers must:
Report all excess remaining USG-provided COVID-19 vaccine inventory using the wastage transaction in their jurisdictional reporting systems.
Properly dispose of those vaccines according to state and local regulations.This reporting requirement is for inventory purposes only and will not be used to judge provider performance. Direct questions about disposal activities to your state or local immunization program.
**Deadline –** These reports and disposal of remaining doses must be completed by October 27, 2023.
**Step Two: Check this CDC Provider Agreement Update Website for Additional Program Close-out Steps**
Providers must check this website for any additional actions required to close out participation in the CDC COVID-19 Vaccination Program.
**Step Three: Using Unexpired Ancillary Supplies**
Until September 12, 2023, all COVID-19 vaccine in the United States had been purchased by the United States Government (USG) for administration exclusively through the CDC COVID-19 Vaccination Program. Providers are prohibited from selling USG-purchased COVID-19 vaccine doses.
In addition, until September 12, 2023, all ancillary supplies provided by the USG through the CDC COVID-19 Vaccination Program could only be used as part of the process for administering USG-provided COVID-19 vaccine doses.
Providers may now use ancillary supplies provided by the USG through the CDC COVID-19 Vaccination Program to administer their commercially purchased vaccines.
**Note**: The expiration date printed on the exterior box of the CDC ancillary kit does not apply to all items in the kit. The date on the external label is based on the earliest expiry of any of the kit’s components.
Providers may exercise discretion and continue using unexpired kit components (e.g., needles and syringes) until they expire. Dispose of expired components in accordance with state and local requirements.
Unexpired ancillary kits or the items contained within **cannot be sold or otherwise exchanged for anything of value**, but can be shared domestically, at no charge, with other immunization programs, including:
Other clinics within the practice
Other sites offering healthcare services
Veterinary clinicsPer federal funding requirements, ancillary kits **cannot be donated outside of the United States** or to organizations that will use the supplies outside the US.
*Again, USG-provided ancillary supplies cannot be sold.*
**Step Four: Participate in Vaccines.gov vaccine locator service**
During the CDC COVID-19 Vaccination Program, the website Vaccines.gov helped the public find the USG-provided COVID-19 vaccines they needed. With the Program over, Vaccines.gov will become a resource for locating providers administering the 2023–2024 COVID-19 vaccines both in the private commercial marketplace and through CDC’s Bridge Access Program.
Providers already participating in Vaccines.gov (including those whose data previously was updated by the jurisdiction public health agency) can update their information using the instructions in the Provider Resources section of Vaccines.gov.
Providers *not* previously enrolled in Vaccines.gov will follow a different process. Instructions will be forthcoming.  Check back on this webpage.Use of Vaccine Recipient Data for Commercial Marketing Purposes Prohibited (5/18/2021)Notwithstanding uses or disclosures otherwise allowed by law, providers are prohibited from using or disclosing data collected from vaccine recipients for and through the CDC COVID-19 Vaccination Program for commercial marketing purposes or for any other purpose not allowed under this updated provision of the COVID-19 Vaccination Provider Agreement. Such data include COVID-19 vaccination registration information and vaccine administration data. These data are collected solely for the purposes of the CDC COVID-19 Vaccination Program and must be maintained in a manner that protects the integrity of the CDC COVID-19 Vaccination Program by only being used or disclosed for the purposes of the COVID-19 Vaccination Program and other limited purposes that promote public health, advance positive patient outcomes, and promote health equity.
This prohibition is not intended to limit communications by health care providers to vaccine recipients with whom the provider has an existing relationship prior to contact about COVID-19 vaccination.
The following are not included in the above prohibition:
Communications regarding receipt of an additional dose of COVID-19 vaccine
Communications to vaccine recipient for public health purposes
Communications to vaccine recipients involving pharmacy or clinical services of the provider, personalized to the vaccine recipient’s medical needs, even if those services are not directly related to COVID-19 vaccination
Availability of other vaccines (e.g., shingles, pneumococcal conjugate, seasonal influenza, routine childhood vaccines)
Clinical emails
Disease screening services
Communications about the availability of programs to manage particular health conditions (e.g., asthma, diabetes, heart disease)In addition, de-identified, aggregate datasets can be used by providers and shared with other partners for public health, population health, and health equity purposes.
Communications with COVID-19 vaccine recipients involving the store component of any pharmacy or other provider enrolled in the CDC COVID-19 Vaccination Program are considered prohibited commercial marketing. For example, text, e-mail, mail, or other communications to COVID-19 vaccine recipients about products on sale in the store are prohibited as commercial marketing.
COVID-19 vaccination registration information and vaccine administration data collected in the course of participation in the CDC COVID-19 Vaccination Program cannot be sold, for direct or indirect remuneration, even with permission of the vaccine recipient.Reporting Suspected Fraud or AbuseIndividuals becoming aware of any suspected fraud or abuse related to the CDC COVID-19 Vaccination Program or violations of provider agreement requirements are encouraged to report them to the Office of the Inspector General, U.S. Department of Health and Human Services at 1-800-HHS-TIPS or TIPS.HHS.GOV.CDC No Longer Distributing COVID-19 Vaccination Record Cards (10/6/23)Providers are no longer required to complete CDC COVID-19 Vaccination Record Cards.Ongoing Requirements to Report Vaccinations to Jurisdiction Immunization Information Systems (10/6/23)Separate from participation in the CDC COVID-19 Vaccination Program, vaccinating providers must submit vaccine administration data for all covered vaccines through the immunization information system (IIS) of the state and local or territorial jurisdiction, as applicable.
Enrolling in your jurisdiction/state-based IIS systemAdditional ResourcesCOVIDVaxView
							
					
							Last Reviewed:  October 6, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeCOVID-19 Vaccination
Product Info by U.S. Vaccineplus icon
EUA
EUI
Interim Clinical Considerationsplus icon
Use of COVID-19 Vaccines in the U.S.
Use of COVID-19 Vaccines in the U.S.: Appendices
FAQs for the Interim Clinical Considerations
Myocarditis and Pericarditis Considerations
Clinical Care
Provider Requirements and Support
Vaccine Recipient Educationplus icon
Talking with Patients about COVID-19 Vaccination
How to Tailor COVID-19 Information to Your Audience
How to Address COVID-19 Vaccine Misinformation
Health Departments
Planning & Partnerships
6 Things to Know
Equity in Childhood COVID-19 Vaccination
COVID-19 Vaccine Data Systemsplus icon
Overviewplus icon
Vaccine IT Overview
Data Reporting Requirements
Vaccine Administration Management System (VAMS)plus icon
Getting Started in VAMS
General Public User
Resources for Jurisdictions, Clinics, and Organizations
VAMS Program Information
Vaccinate with Confidenceplus icon
What Is Vaccine Confidence?
Vaccine Confidence Strategies
Rapid Community Assessment Guide
COVID-19 Vaccine Confidence Data
12 COVID-19 Vaccination Strategies for Your Community
How to Engage the Arts to Build COVID-19 Vaccine Confidence
Strategies for Reaching People with Limited Access to COVID-19 Vaccines


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue